HIV viral load testing and monitoring in Côte d'Ivoire: A survival analysis of viral load testing and suppression, and evaluation of adherence to national recommendations.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
12
2022
accepted:
31
07
2023
medline:
14
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Routine viral load (VL) monitoring is the standard of care in Côte d'Ivoire and allows for effective treatment guidance for people living with human immunodeficiency virus (HIV) to reach viral load suppression (VLS). For VL monitoring to be effective in reducing the impact of HIV, it must be provided in accordance with national guidance. This study aimed to evaluate VL testing, VLS rates and adherence to national guidance for VL testing using data collected from three national laboratories. We collected data on VL testing between 2015-2018 from OpenELIS (OE), an open-source electronic laboratory information system. We merged data by unique patient ID for patients (0-80 years old) who received multiple VL tests to calculate time between tests. We defined VLS as HIV RNA ≤1,000 copies/mL based on Côte d'Ivoire national and WHO guidance at the time of data collection. We used the Kaplan-Meier survival estimator to estimate time between ART (antiretroviral therapy) initiation and the first VL test, time between subsequent VL tests, and to estimate the proportion of people living with HIV (PLHIV) who were virally suppressed within 12 months of ART initiation. At the first documented VL test, 79.6% of patients were virally suppressed (95% CI: 78.9-80.3). Children under 15 were the least likely to be virally suppressed (55.2%, 95% CI: 51.5-58.8). The median time from ART initiation to the first VL sample collection for testing was 7.8 months (IQR:6.2-13.4). 72.4% of patients were virally suppressed within one year of treatment initiation (95% CI:71.5-73.3). Approximately 30% of patients received a second VL test during the 4-year study period. The median time between the first and second VL tests was 24.9 months (IQR: 4.7->40). Most PLHIV received their first VL test within the recommended 12 months of ART initiation but did not receive subsequent VL monitoring tests within the recommended time frame, reducing the benefits of VL monitoring. While VLS was fairly high, children were least likely to be virally suppressed. Our findings highlight the importance of regular VL monitoring after the first VL test, especially for children.
Identifiants
pubmed: 37708102
doi: 10.1371/journal.pgph.0001822
pii: PGPH-D-22-01984
pmc: PMC10501548
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0001822Informations de copyright
Copyright: © 2023 Kemper et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Int AIDS Soc. 2019 Jan;22(1):e25227
pubmed: 30663278
Am J Epidemiol. 2020 Dec 1;189(12):1492-1501
pubmed: 32648905
J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25794
pubmed: 34713578
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1287-90
pubmed: 26605986
J Int AIDS Soc. 2020 Dec;23(12):e25649
pubmed: 33340284
BMC Public Health. 2018 Aug 22;18(1):1048
pubmed: 30134880
Lancet HIV. 2019 Apr;6(4):e211-e213
pubmed: 30772420
J Venom Anim Toxins Incl Trop Dis. 2023 Jul 03;29:e20230002
pubmed: 37405230
Afr J Lab Med. 2021 May 17;10(1):1284
pubmed: 34192117
BMC Med. 2011 May 20;9:59
pubmed: 21599888
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29171172
Public Health Action. 2018 Dec 21;8(4):225-231
pubmed: 30775284
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S71-S80
pubmed: 29994828
Clin Infect Dis. 2016 Dec 15;63(12):1645-1654
pubmed: 27660236
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):775-778
pubmed: 34043612
PLoS One. 2019 Aug 28;14(8):e0220337
pubmed: 31461455
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31
pubmed: 21694603
Stat Methods Med Res. 2010 Feb;19(1):53-70
pubmed: 19654168
J Int AIDS Soc. 2020 May;23(5):e25476
pubmed: 32406983
Int J Med Inform. 2023 Feb;170:104977
pubmed: 36608629
BMC Infect Dis. 2019 May 14;19(1):419
pubmed: 31088496
J Stat Softw. 2010 Aug;36(2):
pubmed: 25285054
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326